The ₹550 Crore Signal
Quadria Group-backed healthcare investor HealthQuad has announced first-close commitments of ₹550 crore for its third fund, HealthQuad Fund III . The amount represents more than one-third of the fund's target corpus of ₹1,700 crore, with a greenshoe option that could take the total to ₹2,500 crore . The fund is expected to close by the middle of next year .
The commitments came from a mix of existing limited partners from HealthQuad's earlier funds, alongside new investors spanning domestic and international fund-of-funds, institutions, and family offices . Sunil Thakur, co-founder of HealthQuad and partner at Quadria Capital, told Mint that the quick fundraise reflects the strength of the opportunity: "There is enough and more demand. And that is being demonstrated by the fundraise that we have done in a very short span of time" .
Where the Money Is Going
HealthQuad Fund III has already made its first investment: an undisclosed commitment to Lifesigns, an AI-powered remote patient monitoring platform . The firm is actively evaluating other proprietary opportunities to build early portfolio visibility .
The fund will focus on early-growth companies across four broad segments: HealthTech, MedTech, Bio/Pharma Tech, and Novel Healthcare Delivery models . These segments are expanding at annual rates of 16 to 40 per cent and are projected to account for over 40 per cent of India's projected $600 billion healthcare market by 2030 .
The Quadria HealthQuad Relationship
HealthQuad was incubated in 2016 by Quadria Group as its dedicated early-growth healthcare investment vehicle . The platform was set up in partnership with KOIS, an impact investment firm, but the two parties mutually separated in 2025. Following the separation, Quadria took full control of HealthQuad, retaining the majority of the investment team while expanding leadership with the addition of Rahul Agarwal and Namit Chugh .
The separation created a clear division of focus. Thakur explained that Quadria will continue to back conventional healthcare businesses such as hospitals, eye care, dialysis, and pharmaceutical manufacturing, while HealthQuad will focus on technology-led models . "Quadria is going to support the conventional form of healthcare. HealthQuad is going to support the new-age healthcare model," he said .
The Track Record
HealthQuad's first two funds backed more than 18 companies, and many of these have since scaled into category leaders . The portfolio includes:
Redcliffe Labs, a diagnostics platform
Wysa, a mental health chatbot
Cureskin, a dermatology platform
Strand Life Sciences, a genomics company
Medikabazaar, a B2B medical supplies platform
Ekincare, a corporate health benefits platform
Rahul Agarwal, partner at HealthQuad, told the Economic Times that the firm is not looking to replace traditional healthcare, but to back models that are assistive, supplementary, and complementary to existing healthcare infrastructure .
The AI Filter
HealthQuad is applying a rigorous filter to AI investments. Agarwal told the Economic Times that the fund will back only "clinical grade AI"—products approved or validated by Indian, US, or European regulators, and trusted by clinicians and healthcare enterprises . This focus on regulatory compliance and clinical trust is designed to ensure that portfolio companies can scale both in India and internationally. "Such asset-light models can travel better to global markets than local, asset-heavy businesses.
The Broader Context
The fundraise comes after the 2020-22 healthtech cycle, when several digital healthcare models attracted significant investor interest but later struggled to prove sustainable demand and unit economics . Agarwal noted that HealthQuad does not back transient themes, but companies that can become category leaders. "Alpha returns come from backing market leaders, not the 10th or 20th company in a segment," he said .
The firm studies companies for two to four years before investing, and about 90 per cent of its deals are proprietary . Its investment team works alongside a clinical advisory board and operating experts to assess whether a model is clinically relevant, regulatory-compliant, and useful for healthcare enterprises over the long term .
The fund also applies a sharper governance filter after a series of blow-ups across the startup ecosystem. HealthQuad's portfolio has included Medikabazaar, which has faced allegations of financial misreporting and an indemnity claim from some investors .
The Bottom Line
HealthQuad's ₹550 crore first close is a vote of confidence in India's new-age healthcare models. With its third fund, the firm is betting that technology-enabled healthcare businesses—from clinical-grade AI diagnostics to novel delivery platforms—are poised to capture a significant share of a rapidly growing market. The quick fundraise and strong pipeline suggest investors share that confidence.
